Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Acquisition
SEC Form 4
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 12,500 common shares on April 1, 2024, due to the release of restrictions from shares awarded on March 31, 2023.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction on April 1, 2024.
- The transaction involved the acquisition of 12,500 common shares.
- These shares were acquired due to the release of restrictions from shares awarded on March 31, 2023.
- Following the transaction, Andrade beneficially owns 104,271 common shares.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation, and doesn't indicate any particularly positive or negative sentiment.
Stakeholder Impact
- The release of restricted shares to a key executive could be viewed positively by stakeholders as it aligns management's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award. |
| 04/01/2024 | Date of transaction (share acquisition). |
| 04/03/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.